| Bioactivity | Lefitolimod sodium is a DNA-based TLR9 agonist and an immune surveillance reactivator. Lefitolimod sodium induces HIV-specific immune responses and can be used for the research of cancer and HIV-1[1][4]. |
| Name | Lefitolimod sodium |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Thomas M, et al. Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study. Ann Oncol. 2018 Oct 1;29(10):2076-2084. [2]. Jin Y, et al. Development of CpG oligodeoxynucleotide TLR9 agonists in anti-cancer therapy. Expert Rev Anticancer Ther. 2021 Aug;21(8):841-851. [3]. Schmidt M, et al. Design and Structural Requirements of the Potent and Safe TLR-9 Agonistic Immunomodulator MGN1703. Nucleic Acid Ther. 2015 Jun;25(3):130-40. [4]. McWhirter SM, et al. Nucleic Acid Sensors as Therapeutic Targets for Human Disease. Immunity. 2020 Jul 14;53(1):78-97. |